Research Studies

Pathway to Prevention screening is the first step for all TrialNet prevention studies. Screening is offered at no cost to eligible individuals to evaluate their personal risk of developing the disease. This unique screening can identify the early stages of type 1 diabetes (T1D) years before any symptoms appear. It also helps researchers learn more about how T1D develops and plan new studies exploring ways to prevent it

Pathway to Prevention screening is the first step for all TrialNet prevention studies. Screening is offered at no cost to eligible individuals to evaluate their personal risk of developing the disease. This unique screening can identify the early stages of type 1 diabetes (T1D) years before any symptoms appear. It also helps researchers learn more about how T1D develops and plan new studies exploring ways to prevent it. Relatives of people with T1D are 15 times more likely to develop T1D.

The goal of this clinical trial is to learn about the effect and safety of a new drug, which may prevent nighttime hypoglycemia. Participants will take the active drug during one of two 4-weeks treatment periods, and placebo during the other and they will wear blinded continuous glucose monitoring (CGM) during both periods. The study also includes 6-7 study visits at Mount Sinai Hospital and 2 phone calls over 16-20 weeks and participants will have to fill in an e-dairy and upload CGM daily

This 26-week trial examines if low dose empagliflozin (2.5 mg/day) alongside automated insulin delivery (AID) enhances glucose control in type 1 diabetes patients not meeting target range (3.9-10.0 mmol/l) when compared to placebo. Participants must be on AID (also called hybrid closed loop) before the study and they will receive either empagliflozin or a placebo during the trial. The study includes 3 in-person visits with bloodwork and multiple phone safety check-ins over 6 months period.

RCT age 1-36 within 100 days of diagnosis of stage 3 (clinical) Type 1 diabetes

There are many surveys that ask people with diabetes about things like distress, fear of low blood sugar, or how satisfied they are with treatment. These surveys can be long, and they don’t always capture what matters most to people living with T1D. We have created a new survey with only two questions. It is designed to be short and simple, while still giving an honest picture of what it feels like to live with T1D. https://redcap.link/evcay2pd.

The University of Calgary is seeking adults living with type 1 diabetes to complete an online survey to better understand patient preferences and risk tolerance relating to the use of a newer class of oral medication that can be taken in addition to insulin.

This study aims to compare the effects of exercise training (combined resistance and aerobic exercise) performed before breakfast to similar training performed after eating breakfast in people with type 1 diabetes. Training sessions will occur at the Physical Activity Diabetes Lab between the hours of 6-11am on any day of the week based on participant’s preference.